The Journal of asthma : official journal of the Association for the Care of Asthma · 2025
The effect of continuous positive airway pressure therapy in patients with expiratory large airway collapse with and without asthma.
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bikov Andras, Hassan M Zahid, Bokhari Saba, Fowler Stephen J
Аннотация
OBJECTIVE: Expiratory large airway collapse (ELAC) is characterized by abnormal (>50%) narrowing of the large airways. It is a potential reason for poor asthma control and increased rate of asthma exacerbations. Continuous positive airway pressure (CPAP) is a potential treatment for ELAC. However, data on adherence to CPAP and its clinical impact in ELAC are limited.
METHODS: Sixty-five patients with ELAC [age 61 (55-70) years, 56 females] who were set up on CPAP between December 2014 and May 2022 were included in this retrospective observational cohort study. Etiologies for ELAC included asthma (n = 47), COPD (n = 4), bronchiectasis (n = 3), relapsing polychondritis (n = 3), and large hiatus hernia compromising the bronchi (n = 1); in 7 cases it was considered idiopathic.
RESULTS: Thirty-nine patients were adherent to CPAP. Adherence was not related to demographics, clinical characteristics or CPAP settings (all p > 0.05). Seventy-seven percent perceived benefits in their respiratory symptoms and 95% reported better sleep. In those with asthma, whilst there was no difference in the daily inhaled corticosteroid dose before and after CPAP (p = 0.90), the annual number of systemic corticosteroid courses decreased following CPAP (p = 0.02).
CONCLUSIONS: CPAP is well tolerated in patients with ELAC, and many report improvement in their respiratory and sleep-related symptoms. There is an additional benefit in patients with concomitant asthma in terms of steroid reduction that needs to be investigated in future studies.
METHODS: Sixty-five patients with ELAC [age 61 (55-70) years, 56 females] who were set up on CPAP between December 2014 and May 2022 were included in this retrospective observational cohort study. Etiologies for ELAC included asthma (n = 47), COPD (n = 4), bronchiectasis (n = 3), relapsing polychondritis (n = 3), and large hiatus hernia compromising the bronchi (n = 1); in 7 cases it was considered idiopathic.
RESULTS: Thirty-nine patients were adherent to CPAP. Adherence was not related to demographics, clinical characteristics or CPAP settings (all p > 0.05). Seventy-seven percent perceived benefits in their respiratory symptoms and 95% reported better sleep. In those with asthma, whilst there was no difference in the daily inhaled corticosteroid dose before and after CPAP (p = 0.90), the annual number of systemic corticosteroid courses decreased following CPAP (p = 0.02).
CONCLUSIONS: CPAP is well tolerated in patients with ELAC, and many report improvement in their respiratory and sleep-related symptoms. There is an additional benefit in patients with concomitant asthma in terms of steroid reduction that needs to be investigated in future studies.